Drug Discovery Stocks List

Symbol Grade Name % Change
ATHX D Athersys, Inc. 3.21
BASI C Bioanalytical Systems, Inc. 1.17
BLRX C BioLineRx Ltd. 5.11
BMRN F BioMarin Pharmaceutical Inc. 1.42
CLVS D Clovis Oncology, Inc. 3.16
CRIS D Curis, Inc. 2.48
INFI D Infinity Pharmaceuticals, Inc. 0.29
IONS F Ionis Pharmaceuticals, Inc. 0.29
LXRX C Lexicon Pharmaceuticals, Inc. 4.10
SUPN B Supernus Pharmaceuticals, Inc. 4.60
CRL C Charles River Laboratories International, Inc. 1.85
GE A General Electric Company 4.21
GLW A Corning Incorporated 2.60
HTGC A Hercules Technology Growth Capital, Inc. 2.69
IEX B IDEX Corporation 0.57
PKI F PerkinElmer, Inc. -1.71
WAT C Waters Corporation 0.37
GLYC F GlycoMimetics, Inc. -0.57
BLFS F BioLife Solutions, Inc. 1.01
LRMR F Larimar Therapeutics, Inc. -3.06
BBC C Virtus LifeSci Biotech Clinical Trials ETF 2.04
SMMT D Summit Therapeutics plc 2.60
SRRA F Sierra Oncology, Inc. 0.72
HCM D Hutchison China MediTech Limited -0.03
VTGN C VistaGen Therapeutics, Inc. -5.22
TPVY F TriplePoint Venture Growth BDC Corp. 5.75% Notes due 2022 -0.20
NCNA D NuCana plc 2.91
STRO F Sutro Biopharma, Inc. 5.64
TWST F Twist Bioscience Corporation 5.11
MREO B Mereo BioPharma Group plc 4.42
IDYA B IDEAYA Biosciences, Inc. 6.09
BCEL C Atreca, Inc. 5.57
ADPT D Adaptive Biotechnologies Corporation 2.87
BNTX C BioNTech SE 1.96
LMNL F Liminal BioSciences Inc. -1.83
SDGR B Schrodinger, Inc. 1.97
RLAY F Relay Therapeutics, Inc. 6.99
CMPS C COMPASS Pathways Plc -2.57
VGAC F VG Acquisition Corp. / 23andMe 3.64
LIXT C Lixte Biotechnology Holdings, Inc. 9.57
CERT D Certara, Inc. -0.55
View As Page of Charts


Related ETFs - A few ETFs which own one or more of the above listed Drug Discovery stocks.

Recent Signals

Date Stock Signal Type
2021-02-24 ADPT Slingshot Bearish Bearish Swing Setup
2021-02-24 ATHX 200 DMA Resistance Bearish
2021-02-24 ATHX New Uptrend Bullish
2021-02-24 BASI Narrow Range Bar Range Contraction
2021-02-24 BASI NR7 Range Contraction
2021-02-24 BBC Calm After Storm Range Contraction
2021-02-24 BLFS MACD Bearish Centerline Cross Bearish
2021-02-24 BLRX NR7 Range Contraction
2021-02-24 BMRN 20 DMA Resistance Bearish
2021-02-24 BMRN Slingshot Bearish Bearish Swing Setup
2021-02-24 BNTX Bollinger Band Squeeze Range Contraction
2021-02-24 CERT 20 DMA Resistance Bearish
2021-02-24 CLVS MACD Bearish Centerline Cross Bearish
2021-02-24 CLVS Narrow Range Bar Range Contraction
2021-02-24 CLVS NR7 Range Contraction
2021-02-24 CLVS Crossed Above 200 DMA Bullish
2021-02-24 CMPS Upper Bollinger Band Walk Strength
2021-02-24 CMPS 50 DMA Support Bullish
2021-02-24 CRIS 50 DMA Support Bullish
2021-02-24 GE Stochastic Sell Signal Bearish
2021-02-24 GE Pocket Pivot Bullish Swing Setup
2021-02-24 GE Expansion Breakout Bullish Swing Setup
2021-02-24 GE Upper Bollinger Band Walk Strength
2021-02-24 GE New 52 Week High Strength
2021-02-24 GE New 52 Week Closing High Bullish
2021-02-24 GLW New 52 Week Closing High Bullish
2021-02-24 GLYC Lower Bollinger Band Walk Weakness
2021-02-24 GLYC Stochastic Reached Oversold Weakness
2021-02-24 HTGC New Uptrend Bullish
2021-02-24 HTGC New 52 Week High Strength
2021-02-24 HTGC New 52 Week Closing High Bullish
2021-02-24 HTGC Expansion Breakout Bullish Swing Setup
2021-02-24 HTGC MACD Bullish Signal Line Cross Bullish
2021-02-24 HTGC Pocket Pivot Bullish Swing Setup
2021-02-24 IDYA Pocket Pivot Bullish Swing Setup
2021-02-24 IDYA Crossed Above 20 DMA Bullish
2021-02-24 IEX 50 DMA Support Bullish
2021-02-24 INFI Narrow Range Bar Range Contraction
2021-02-24 INFI NR7 Range Contraction
2021-02-24 LIXT MACD Bullish Signal Line Cross Bullish
2021-02-24 LIXT Pocket Pivot Bullish Swing Setup
2021-02-24 LMNL NR7 Range Contraction
2021-02-24 LMNL Fell Below 20 DMA Bearish
2021-02-24 LMNL MACD Bearish Signal Line Cross Bearish
2021-02-24 LMNL Spinning Top Other
2021-02-24 LRMR MACD Bearish Signal Line Cross Bearish
2021-02-24 LRMR 20 DMA Resistance Bearish
2021-02-24 LXRX 20 DMA Resistance Bearish
2021-02-24 MREO Calm After Storm Range Contraction
2021-02-24 NCNA Expansion Pivot Buy Setup Bullish Swing Setup
2021-02-24 NCNA 20 DMA Resistance Bearish
2021-02-24 NCNA Shooting Star Candlestick Bearish
2021-02-24 NCNA New Uptrend Bullish
2021-02-24 NCNA Stochastic Buy Signal Bullish
2021-02-24 PKI 180 Bearish Setup Bearish Swing Setup
2021-02-24 PKI Lower Bollinger Band Walk Weakness
2021-02-24 SDGR MACD Bullish Signal Line Cross Bullish
2021-02-24 SDGR Calm After Storm Range Contraction
2021-02-24 SMMT NR7 Range Contraction
2021-02-24 SMMT Stochastic Buy Signal Bullish
2021-02-24 SRRA Narrow Range Bar Range Contraction
2021-02-24 SRRA Slingshot Bearish Bearish Swing Setup
2021-02-24 SRRA Stochastic Buy Signal Bullish
2021-02-24 SRRA NR7 Range Contraction
2021-02-24 STRO Bullish Engulfing Bullish
2021-02-24 SUPN Pocket Pivot Bullish Swing Setup
2021-02-24 SUPN New Uptrend Bullish
2021-02-24 SUPN Crossed Above 20 DMA Bullish
2021-02-24 TPVY Bollinger Band Squeeze Range Contraction
2021-02-24 TPVY Narrow Range Bar Range Contraction
2021-02-24 TWST Slingshot Bearish Bearish Swing Setup
2021-02-24 VGAC MACD Bearish Centerline Cross Bearish
2021-02-24 WAT Crossed Above 20 DMA Bullish

Recent News for Drug Discovery Stocks

Date Stock Title
Feb 24 ADPT Adaptive Biotechnologies: Q4 Earnings Insights
Feb 24 BNTX Moderna Sparks On Plans To Test New Covid Vaccine Against Viral Mutant
Feb 24 ADPT Adaptive Biotechnologies EPS misses by $0.04, beats on revenue
Feb 24 BNTX Moderna Ships Updated Covid-19 Vaccine to NIH for Testing
Feb 24 BNTX Moderna expands vaccine production, sets 2022 target of 1.4B doses
Feb 24 ADPT Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2020 Financial Results
Feb 24 IONS Ionis Pharmaceuticals, Inc. (IONS) CEO Brett Monia on Q4 2020 Results - Earnings Call Transcript
Feb 24 TWST Twist Bioscience Launches Methylation Detection Systems
Feb 24 BNTX Global COVID cases fall for a sixth straight week as hopes for J&J vaccine are bolstered by FDA data
Feb 24 BNTX Johnson & Johnson Nabs FDA Endorsement For Covid Shot Ahead Of Key Meeting
Feb 24 GE Altair Acquires Flow Simulator From GE Aviation For Undisclosed Terms
Feb 24 TWST Twist launches NGS methylation detection system for liquid biopsy cancer analysis
Feb 24 BASI Bioanalytical Systems, Inc., doing business as Inotiv, Invests in Laboratory Infrastructure and Data and Study Management Technologies
Feb 24 WAT Waters and TetraScience Partner to Deliver New Levels of Data Access and Insights with Empower Data Science Link
Feb 24 HTGC Hercules Capital Posts Better-Than-Expected 4Q Results; Shares Gain Pre-Market
Feb 24 TWST Twist Bioscience Launches Industry-Leading NGS Methylation Detection System for Liquid Biopsy Cancer Analysis and Epigenetic Studies
Feb 24 GE Altair acquires Flow Simulator from GE to expand into new industries
Feb 24 IONS The Daily Biotech Pulse: Bausch Calls Truce With Icahn, Pfizer's Brain Inflammation Vaccine Gets Priority Review, BriaCell IPO
Feb 24 ADPT The Daily Biotech Pulse: Bausch Calls Truce With Icahn, Pfizer's Brain Inflammation Vaccine Gets Priority Review, BriaCell IPO
Feb 24 IONS Ionis Pharmaceuticals EPS misses by $2.70, beats on revenue

In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered. Historically, drugs were discovered through identifying the active ingredient from traditional remedies or by serendipitous discovery. Later chemical libraries of synthetic small molecules, natural products or extracts were screened in intact cells or whole organisms to identify substances that have a desirable therapeutic effect in a process known as
classical pharmacology. Since sequencing of the human genome which allowed rapid cloning and synthesis of large quantities of purified proteins, it has become common practice to use high throughput screening of large compounds libraries against isolated biological targets which are hypothesized to be disease modifying in a process known as reverse pharmacology. Hits from these screens are then tested in cells and then in animals for efficacy.
Modern drug discovery involves the identification of screening hits, medicinal chemistry and optimization of those hits to increase the affinity, selectivity (to reduce the potential of side effects), efficacy/potency, metabolic stability (to increase the half-life), and oral bioavailability. Once a compound that fulfills all of these requirements has been identified, it will begin the process of drug development prior to clinical trials. One or more of these steps may, but not necessarily, involve computer-aided drug design. Modern drug discovery is thus usually a capital-intensive process that involves large investments by pharmaceutical industry corporations as well as national governments (who provide grants and loan guarantees). Despite advances in technology and understanding of biological systems, drug discovery is still a lengthy, "expensive, difficult, and inefficient process" with low rate of new therapeutic discovery. In 2010, the research and development cost of each new molecular entity was about US$1.8 billion. Drug discovery is done by pharmaceutical companies, with research assistance from universities. The "final product" of drug discovery is a patent on the potential drug. The drug requires very expensive Phase I, II and III clinical trials, and most of them fail. Small companies have a critical role, often then selling the rights to larger companies that have the resources to run the clinical trials.
Discovering drugs that may be a commercial success, or a public health success, involves a complex interaction between investors, industry, academia, patent laws, regulatory exclusivity, marketing and the need to balance secrecy with communication. Meanwhile, for disorders whose rarity means that no large commercial success or public health effect can be expected, the orphan drug funding process ensures that people who experience those disorders can have some hope of pharmacotherapeutic advances.

More about Drug Discovery
Browse All Tags